Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.

Journal of thrombosis and haemostasis : JTH - 1 Apr 2012

Verhoef T I, Redekop W K, Buikema M M, Schalekamp T, Van Der Meer F J M, Le Cessie S, Wessels J A M, Van Schie R M F, De Boer A, Teichert M, Visser L E, Maitland-Van Der Zee A H

Abstract excerpt

BACKGROUND: The required acenocoumarol dose and the risk of underanticoagulation and overanticoagulation are associated with the CYP2C9 and VKORC1 genotypes. However, the duration of the effects of these genes on anticoagulation is not yet known. OBJECTIVES: In the present study, the effects of these polymorphisms on the risk of underanticoagulation and overanticoagulation over time after the start of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Blood Coagulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Drug Administration Schedule

Share to Drug Dosage Calculations

Share to Drug Monitoring

Share to International Normalized Ratio

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 22252093
DOI: 10.1111/j.1538-7836.2012.04633.x

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.PMID 22252093Read ↗

Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.Semantic proximity Read ↗

Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.Semantic proximity Read ↗

Pharmacogenetics role in the safety of acenocoumarol therapy.Semantic proximity Read ↗

Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.Semantic proximity Read ↗

CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.Semantic proximity Read ↗

An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.Semantic proximity Read ↗

Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.Semantic proximity Read ↗

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.Semantic proximity Read ↗

Pharmacogenetics aspects of oral anticoagulants therapy.Semantic proximity Read ↗

The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.